Literature DB >> 25061910

Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma.

U Metser1, D Hussey, G Murphy.   

Abstract

Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the evidence-based utilization of fluorine-18 fludeoxyglucose positron emission tomography ((18)F-FDG PET)/CT in aggressive lymphomas, the utility of PET in FL remains controversial and varies across different jurisdictions. The management of patients with FL differs from aggressive lymphomas and is usually reserved for patients with localized disease in whom long-term control may potentially be achieved by involved field radiotherapy, or for symptomatic patients with advanced-stage disease in whom systemic therapy is indicated. There is a growing body of literature supporting the use of PET/CT in initial staging of FL to guide management decisions. In this review, we summarize the existing literature and present cases from our experience to illustrate current knowledge on the potential role of (18)F-FDG PET/CT in FL.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25061910      PMCID： PMC4170869          DOI： 10.1259/bjr.20140360

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  12 in total

1.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

2.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Authors:  Judith Trotman; Marion Fournier; Thierry Lamy; John Francis Seymour; Anne Sonet; Andrea Janikova; Ofer Shpilberg; Emmanuel Gyan; Hervé Tilly; Jane Estell; Cecily Forsyth; Didier Decaudin; Bettina Fabiani; Jean Gabarre; Bruno Salles; Eric Van Den Neste; Danielle Canioni; Etienne Garin; Michael Fulham; Thierry Vander Borght; Gilles Salles
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

4.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

Authors:  S J Horning; S A Rosenberg
Journal:  N Engl J Med       Date:  1984-12-06       Impact factor: 91.245

5.  Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy.

Authors:  Beverly A Guadagnolo; Sigui Li; Donna Neuberg; Andrea Ng; Ling Hua; Barbara Silver; Mary Ann Stevenson; Peter Mauch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-21       Impact factor: 7.038

6.  Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma.

Authors:  Andrew Wirth; Marcus Foo; John F Seymour; Michael P Macmanus; Rodney J Hicks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-04       Impact factor: 7.038

7.  Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.

Authors:  Jehan Dupuis; Alina Berriolo-Riedinger; Anne Julian; Pauline Brice; Christelle Tychyj-Pinel; Hervé Tilly; Nicolas Mounier; Andrea Gallamini; Pierre Feugier; Pierre Soubeyran; Philippe Colombat; Guy Laurent; Nathalie Berenger; Rene-Olivier Casasnovas; Pierre Vera; Gaetano Paone; Luc Xerri; Gilles Salles; Corinne Haioun; Michel Meignan
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.

Authors:  Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Philippe Moreau; Loïc Campion; Benoît Dupas; Steven Le Gouill
Journal:  Haematologica       Date:  2008-03       Impact factor: 9.941

10.  NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.

Authors:  Donald A Podoloff; Ranjana H Advani; Craig Allred; Al B Benson; Elizabeth Brown; Harold J Burstein; Robert W Carlson; R Edward Coleman; Myron S Czuczman; Dominique Delbeke; Stephen B Edge; David S Ettinger; Frederic W Grannis; Bruce E Hillner; John M Hoffman; Krystyna Kiel; Ritsuko Komaki; Steven M Larson; David A Mankoff; Kenneth E Rosenzweig; John M Skibber; Joachim Yahalom; Jq Michael Yu; Andrew D Zelenetz
Journal:  J Natl Compr Canc Netw       Date:  2007-05       Impact factor: 11.908
View more
  7 in total

Review 1.  Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT.

Authors:  Michael J McKay; Kim L Taubman; Szeting Lee; Andrew M Scott
Journal:  Ann Nucl Med       Date:  2022-01-14       Impact factor: 2.668

2.  Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma.

Authors:  Ajay Major; Andrew Hammes; Matthew Q Schmidt; Rustain Morgan; Diana Abbott; Manali Kamdar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-09-28

3.  Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma.

Authors:  Yeye Zhou; Zixuan Zhao; Yiwei Wu; Jihui Li; Bin Zhang; Shibiao Sang; Shengming Deng
Journal:  Cancer Manag Res       Date:  2019-07-23       Impact factor: 3.602

4.  Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma.

Authors:  Julie Faudemer; Nicolas Aide; Anne-Claire Gac; Ghandi Damaj; Jean-Pierre Vilque; Charline Lasnon
Journal:  Sci Rep       Date:  2021-12-10       Impact factor: 4.379

5.  Primary Gastrointestinal Follicular Lymphomas: A Prospective Study of 31 Patients with Long-term Follow-up Registered in the French Gastrointestinal Lymphoma Study Group (GELD) of the French Federation of Digestive Oncology (FFCD).

Authors:  Tamara Matysiak-Budnik; Philippe Jamet; Nicolas Chapelle; Bettina Fabiani; Paul Coppo; Agnès Ruskoné-Fourmestraux
Journal:  Gut Liver       Date:  2022-03-15       Impact factor: 4.519

6.  Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT.

Authors:  Hongyan Li; Min Wang; Yajing Zhang; Fan Hu; Kun Wang; Chenyang Wang; Zairong Gao
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

7.  Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma.

Authors:  Hyun Joo Kim; Reeree Lee; Hongyoon Choi; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2018-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.